

Presentation Number	Author Name & Surname	Institution	Country	Poster Title	Session	Date	Time	Room
OP-19	Zeynep Karakas	Istanbul Faculty of Medicine, Istanbul University	TURKEY	TWO YEARS EXPERIENCE OF A MULTIDISCIPLINARY APPROACH FOR PEDIATRIC THROMBOSIS IN A TERTIARY REFERRAL CENTER	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	1
OP-20	Zorica Cvetkovic	Medical Faculty University of Belgrade, Clinical Hospital Centre Zemun	SERBIA	THE SIGNIFICANCE OF GERIATRIC ASSESSMENT IN ELDERLY PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA: A SINGLE CENTRE EXPERIENCE	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	1
OP-21	Seda Turgut	Bezmailem Vakif University	TURKEY	THE INCIDENCE AND CLINICAL IMPACT OF ENDOCRINE INCIDENTALOMAS IN HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER EXPERIENCE	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	1
OP-22	Fatma Savran Oguz	Istanbul Faculty of Medicine, Istanbul University	TURKEY	CLINICAL RELEVANCE OF MINOR HISTOCOMPATIBILITY ANTIGENS	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	1
OP-23	Ghada Elgohary	Ain Shams University	EGYPT	FEASIBILITY OF THE ARABIC VERSION OF DISTRESS THERMOMETER FOR EGYPTIAN PATIENTS WITH SOLID CANCERS AND HEMATOLOGICAL MALIGNANCIES	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	1
OP-24	Ayten Shirinova	Institute of Hematology and Transfusiology	AZERBAIJAN	THE CURRENT SITUATION OF MULTIPLE MYELOMA IN AZERBAIJAN.	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	2
OP-25	Aypara Hasanova	Institute of Hematology and Transfusiology	AZERBAIJAN	CYP3A5*3, CYP3A4*18 AND CYP2B6 GENE POLYMORPHISMS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN AZERBAIJAN	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	2
OP-26	Timur Valiev	N. N. Blokhin National Cancer Research Center of the Ministry of Health of Russian Federation	RUSSIA	RITUXIMAB REDUCTION FOR PEDIATRIC ADVANCED-STAGE BURKITT LYMPHOMA	BEST SELECTED ORAL PRESENTATIONS SESSION	9 October 2020	14.40 - 14.50	MAIN HALL
OP-27	Mahasen Alsaleh	King Faisal Specialist Hospital & Research Centre	SAUDI ARABIA	INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN CHILDHOOD CANCERS FROM A TERTIARY CARE CENTRE	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	2
OP-28	Larisa Girshova	Federal Almazov National Medical Research Centre	RUSSIA	AZA MAINTENANCE AFTER CONSOLIDATION INCREASE RFS IN MRDVE+ LOW AND NOT IN INTERMEDIATE RISK AML PATIENTS	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	2
OP-29	Esra Turan Erkek	The Health Science University, Dr. L. Kirdar Education and Research Hospital	TURKEY	SYNCHRONOUS GASTRIC MALT LYMPHOMA AND ADENOCARCINOMA WITH CONCURRENT PULMONARY MALT LYMPHOMA	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	2
OP-30	Carmino De Souza	University of Campinas - UNICAMP	BRAZIL	T-CELL BRAZIL PROJECT: PRELIMINARY RESULTS AFTER 2 YEARS OF T-CELL LYMPHOMA REGISTRY	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	3
OP-31	Noha Elkoney	Faculty of Medicine, Alexandria University	EGYPT	SH2-CONTAINING TYROSINE PHOSPHATASE-1 (SHP-1) mRNA EXPRESSION AND ITS PROMOTER METHYLATION IN IMATINIB RESPONSE IN EGYPTIAN CHRONIC MYELOID LEUKEMIA PATIENTS	BEST SELECTED ORAL PRESENTATIONS SESSION	9 October 2020	14.10 - 14.20	MAIN HALL
OP-32	MuratOzbalak	Istanbul Faculty of Medicine, Istanbul University	TURKEY	A RETROSPECTIVE ANALYSIS OF PERIPHERAL T-CELL LYMPHOMA PATIENTS: SINGLE CENTER	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	3
OP-33	Shafaq Maqsood	Shaukat Khanum Memorial Cancer Hospital and Research Centre	PAKISTAN	CHARACTERISTICS AND OUTCOME OF PATIENTS WITH HEMATOLOGICAL MALIGNANCY ADMITTED TO INTENSIVE CARE UNIT- A SINGLE CENTRE EXPERIENCE.	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	3
OP-36	Fatih Kose	Baskent University	TURKEY	CLINICAL CHARACTERISTICS OF RELAPSED OVARIAN CANCER PATIENTS WITH STRIKING RESPONSE TO THE BEVACIZUMAB AT FIRST RELAPSE	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	3
OP-38	Fatih Kose	Baskent University	TURKEY	INITIAL PRESENTATION OF PROSTATE CANCER MAY HINT DIFFERENT CLINICAL CHARACTERISTICS ALONG WITH SERVING PREDICTIVE BIOMARKER IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE	ORAL PRESENTATIONS SESSION II	10 October 2019	07.30 - 08.15	3